Uppsala, Sweden – 1 April 2025
Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its TEAD degrader programme has been selected for a late-breaking presentation at the American Association for Cancer Research’s Annual Meeting 2025. The conference will take place on April 25–30, 2025 in Chicago, Illinois.
Dr Peter Brandt, Head of Chemistry, will present a poster entitled Expanding the TEAD Therapeutic Potential with Degraders: In Vitro Sensitivity, Predictive Biomarkers, and In Vivo Efficacy on Monday April 28, 2025, at 2:00 PM – 5:00 PM. The location is at the McCormick Place Convention Center, Section 54, abstract presentation number: LB238. The session title is Late-Breaking Research: Experimental and Molecular Therapeutics 2.
The presentation will include new positive results from studies with novel targeted protein degraders (TPDs) of TEAD based on interface 3-binding ligands under development by Beactica. This will include efficacy data from a viability screen of 845 human cancer cell lines representing over 45 major types of cancer, identification of novel potential biomarkers for patient selection, and in vivo data confirming degradation of TEAD in target tissue. The work to be presented contains contributions by Beactica’s collaborators at the Broad Institute of MIT and Harvard.
Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world. It has an anticipated attendance of more than 20 000 scientists, clinicians, advocates, and other attendees. The event spans integrative cancer science, global impact, individualised patient care and showcases the best and most up-to-date cancer science available.
About TEAD
TEAD 1–4 (Transcriptional Enhanced Associate Domain) are transcription factors that together with its coactivators YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif) play key roles in the Hippo signalling pathway that regulates cell proliferation, apoptosis, and stemness. Dysregulation of the Hippo pathway and subsequent activation of TEAD has been reported in a wide range of cancers such as squamous cell carcinoma, head and neck, gynaecological, and gastrointestinal cancers. The first clinical proof-of-concept for drugging the Hippo–YAP–TEAD pathway was achieved with the TEAD inhibitor VT3989 and was presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2023.
About Beactica Therapeutics
Beactica Therapeutics AB is a privately held precision oncology company committed to the fight against cancer. The company is advancing a pipeline of novel small molecule therapeutics with a focus to treat genetically defined cancers with significant unmet medical need. Beactica’s approach is centered around targeting synthetically lethal disease proteins with allosteric modulators and targeted protein degraders. Beactica deliver value to patients and shareholders by advancing its programmes to clinical proof of concept. For more information, please visit www.beactica.com.
Related files:
Read more news from Beactica Therapeutics here.
Stay Updated
Sign up for the Beactica newsletter to receive our latest news and updates